Novartis, Hyrbidon to Develop Asthma, Allergy Drugs

Novartis AG and Hyrbidon Inc. have entered into research collaboration and license agreements for the development and commercialisation of new asthma and allergy drugs based on Hybridon's IMO technology platform.

()a href="http://www.forbes.com/home/feeds/afx/2005/06/01/afx2068616.html" target="_blank">Forbes